becton dickinson Archives - Page 2 of 6

BD to spin off its diabetes business, Q2 earnings beat The Street

BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022.

The Diabetes Care business saw $1.1 billion in sales during BD’s fiscal year ended Sept. 30, 2020, nearly half outside the U.S. The business manufactures roughly 8 billion injection devices annually, serving about 30 million patients. The new company will have manufacturing sites in the United States, Ireland and China and expected office locations in New Jersey and Massachusetts.

Get the full story on our sister site Drug Delivery Business News.

Another BD Alaris infusion pump recall is Class I

The FDA has identified another recall for the Alaris infusion pump from BD (NYSE:BDX) as Class I, the most serious kind of recall.

BD’s latest recall, initiated on March 3, 2021, involves its BD Alaris infusion pump module system, which includes an infusion pump and vital signs monitoring system with a PC unit, the Guardrails Suite MX and up to four removable infusion or monitoring modules (channels), according to an FDA notice.

Get the full story at our sister site, Drug Delivery Business News.

FDA authorizes use of over-the-counter COVID-19 tests for screening

The FDA announced today that it authorized several COVID-19 tests for over-the-counter use in asymptomatic screening.

Among the tests authorized were the BinaxNow Ag card from Abbott (which includes point-of-care screening), the Quidel Quick-View at-home test and the BD Veritor Plus system, which was authorized for POC screening with a prescription.

“BD is supporting the global efforts to return to normalcy as soon as possible, and this additional authorization for the BD Veritor system to be used in screening through serial testing of asymptomatic individuals is a large step forward,” BD life sciences president Dave Hickey said in a news release. “Frequent testing of individuals without symptoms will enable those with negative results to resume their normal school or work routines and will help to identify and isolate positive cases of COVID-19 as early as possible to prevent further spread.

“Screening through serial testing is a…

BD plans $65M plant in Arizona

BD (NYSE:BDX) announced today that it will invest $65 million to build a state-of-the-art supply chain hub in Tucson, Ariz.

Franklin Lakes, N.J.-based BD’s new 120,000 square-foot facility is slated to become a hub for the company’s supply chain by serving as a final-stage manufacturing and sterilization center, according to a news release.

Get the full story at our sister site, Medical Design & Outsourcing.

BD plans $65M plant in Arizona

BD (NYSE:BDX) announced today that it will invest $65 million to build a state-of-the-art supply chain hub in Tucson, Ariz.

Franklin Lakes, N.J.-based BD’s new 120,000 square-foot facility is slated to become a hub for the company’s supply chain by serving as a final-stage manufacturing and sterilization center, according to a news release.

Built on approximately 32 acres at the northeast corner of Valencia and Kolb Road in Tucson, the $65 million facility is expected to be made operational in mid-2022, with 40 new jobs, including engineers, scientists, quality control specialists and others set to be added.

Sun Corridor projected that BD’s investment in the Tucson facility will produce a $122 million economic impact ranging over the next 10 years, BD said. The new facility adds to BD’s footprint in Arizona, which includes a $1 billion peripheral intervention business unit headquartered in Tempe.

Tucson was selected as it i…

BD lands EUA for COVID/flu test

The FDA issued a letter to BD (NYSE:BDX) to confirm the emergency use authorization of its Veritor system for detecting COVID-19 and flu.

According to the letter, dated last week, the Veritor system was authorized for the simultaneous qualitative detection and differentiation of SARS-CoV-2 nucleocapsid antigen and/or influenza A and B nucleoprotein antigens directly from anterior nasal swab samples taken from those suspected of a viral respiratory infection.

Use of the test under the EUA is limited only to authorized laboratories, which will analyze tests for those who are suspected of the infection by a healthcare provider within the first six days of symptom onset.

BD’s Veritor diagnostic analysis platform has been a mainstay in the COVID-19 testing space over the past year, with the company receiving several government contracts to produce a variety of tests, including rapid, point-of-care antigen diagnostics.

Issues did arise with report…

BD expands recall of ChloraPrep 3 ml applicator

BD announced that revised a previous press release from last week to expand a voluntary recall of its ChloraPrep 3 mL applicator.

Franklin Lakes, N.J.-based BD initiated the recall for specified catalog numbers of the applicator device on June 23, 2020, as a result of possible fungal contamination under certain environmental conditions, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

BD partners with ImageMover for COVID-19 test mobile app

Becton Dickinson (NYSE:BDX) announced today that it entered into an agreement with ImageMover to offer a mobile app for COVID-19 testing.

Franklin Lakes, N.J.-based Becton Dickinson’s agreement enables the ImageMover software platform to simplify medical data collection and management through a companion mobile app for SARS-CoV-2 antigen testing performed on the BD Veritor Plus system, according to a news release.

The ImageMover app is being made immediately available for BD Veritor Plus system customers as the tests are used at everyday locations like schools and businesses.

BD Veritor Plus has built-in functionality to allow for data sharing to electronic health records through the company’s BD Synapsys informatics platform, which requires an information technology infrastructure commonly seen in healthcare facilities. The collaboration with ImageMover allows for seamless and secure data sharing for everyday locations that don’t have …

MedTech 100 roundup: Industry sees largest fall since October

The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months.

MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a month, the fall has been more than seven points from the end-of-week tally of 110.63 points on Feb. 12.

Medtech’s lowest point of the week was on Thursday, March 4, when it fell to 102.85. The overall drop of about five points from the 107.88-point mark set on Monday, March 1, is the largest dip since the index slid from 97.2 to 91.01 between Oct. 23, 2020, and Oct. 30, 2020.

The all-time best for the index was 110.96, set just three days after that. The index had never reached even the 100-point mark before November 2020.

Still, the industry is in much better condition than it was around this time last year. Medtech’s latest mark means …

Becton Dickinson acquires smart medication device maker GSL Solutions

Becton Dickinson (NYSE:BDX) announced today that it acquired smart medication device developer GSL solutions for an undisclosed amount.

Franklin Lakes, N.J.-based BD said in a news release that GSL Solutions develops devices for storing and tracking controlled substances, as well as patient-specific medications that improve the security, efficiency and compliance of medication storage. Additionally, the company possesses analytic capabilities to further improve inventory management of controlled substances, regulatory compliance and patient safety.

Get the full story at our sister site, Drug Delivery Business News.

Becton Dickinson acquires smart medication device maker GSL Solutions

Becton Dickinson (NYSE:BDX) announced today that it acquired smart medication device developer GSL solutions for an undisclosed amount.

Franklin Lakes, N.J.-based BD said in a news release that GSL Solutions develops devices for storing and tracking controlled substances, as well as patient-specific medications that improve the security, efficiency and compliance of medication storage. Additionally, the company possesses analytic capabilities to further improve inventory management of controlled substances, regulatory compliance and patient safety.

Get the full story at our sister site, Drug Delivery Business News.

N.J. appeals court tosses $83M pelvic mesh verdicts against J&J, Bard

A New Jersey appeals court yesterday threw out jury verdicts totaling $83 million in separate pelvic mesh lawsuits against Johnson & Johnson’s (NYSE:JNJ) Ethicon division and Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard.

In both cases, Bergen County, N.J. judges erred by disallowing evidence showing that each company’s mesh product had received FDA 510 (k) clearance, according to the appeals court panel.

In the case against J&J’s Ethicon, a jury had awarded Elizabeth and Tadeusz Hrymoc $5 million in compensatory damages and $10 million in punitive damages after finding the companies liable for violating New Jersey laws on defective design of their ProLift pelvic mesh and failing to warn patients of product risk.

The jury in the case brought by Mary McGinnis and Thomas Walsh McGinnis found Bard liable for design and failure-to-warn defects under the product liability laws of North Carolina, the plaintiffs’ home state, …